By


Dr. Sean Lyden Agrees to Assume the Role of Chief Medical Consultant and Join the VESTECK Scientific Advisory Board

See more here

By


Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

See more here

By


Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

See more here

By


BioAdvance Breaks Life Sciences Investing Record Year in 2022

Nearly $5 million invested in eight new promising Mid-Atlantic life sciences companies

See more here

By


Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update

See more here

By


Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

– IMM20059, Immunome’s epsin 1 (EPN1)-specific antibody, binds to the surface of multiple tumor cell lines, including lung, breast and prostate cancers in preclinical testing

– EPN1 appears to play an important role in cancer formation and progression, and IMM20059 may have the ability to improve response to immunotherapy

– Combinatorial effect (> 50% reduction in tumor volume) was demonstrated with IMM20059 and anti-PD-L1 treatment atezolizumab

See more here

By


ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy

ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint

See more here

By


ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference

See more here

By


Senzo Receives Funding from the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test

See more here